NTN1 and Parkinson disease: In the 6‐hyroxydopamine‐lesioned rat model and A53T‐SNCA mouse PD model, a similar therapeutic potential exists for overexpressing NTN‐1 and injecting recombinant NTN‐1 into the brain.20